Literature DB >> 34252309

Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.

Laurent Poirel1,2,3, Mustafa Sadek1,4, Patrice Nordmann1,2,3,5.   

Abstract

Cefiderocol (FDC) is a recently developed siderophore cephalosporin showing excellent antibacterial activity against Gram-negative bacteria, including Acinetobacter baumannii. By investigating a series of A. baumannii clinical isolates with elevated MICs of FDC, we showed that PER-like β-lactamases and, to a lesser extent, NDM-like β-lactamases, significantly contributed to reduced susceptibility to that antibiotic. Interestingly, we showed that combination of FDC with avibactam exhibited excellent activity against all multidrug-resistant isolates coproducing OXA-23 and PER-type β-lactamases.

Entities:  

Keywords:  Acinetobacter baumannii; NDM; PER; PER-type β-lactamase; beta-lactamase; cefiderocol; susceptibility testing

Mesh:

Substances:

Year:  2021        PMID: 34252309      PMCID: PMC8448131          DOI: 10.1128/AAC.00877-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain.

Authors:  Pilar Villalón; Sylvia Valdezate; Maria J Medina-Pascual; Virginia Rubio; Ana Vindel; Juan A Saez-Nieto
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

2.  Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases.

Authors:  Tsukasa Ito-Horiyama; Yoshikazu Ishii; Akinobu Ito; Takafumi Sato; Rio Nakamura; Norio Fukuhara; Masakatsu Tsuji; Yoshinori Yamano; Keizo Yamaguchi; Kazuhiro Tateda
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  High prevalence of the PER-1 gene among carbapenem-resistant Acinetobacter baumannii in Riyadh, Saudi Arabia.

Authors:  M M Aly; N M Abu Alsoud; M S Elrobh; S M Al Johani; H H Balkhy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-16       Impact factor: 3.267

Review 4.  Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.

Authors:  Roopali Sharma; Tae Eun Park; Stanley Moy
Journal:  Clin Ther       Date:  2016-03-02       Impact factor: 3.393

5.  Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City.

Authors:  Alejandro Iregui; Zeb Khan; David Landman; John Quale
Journal:  Microb Drug Resist       Date:  2020-02-07       Impact factor: 3.431

6.  Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.

Authors:  Takafumi Sato; Kenji Yamawaki
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

7.  In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.

Authors:  Yoshinori Yamano
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

8.  Diversity of multi-drug resistant Acinetobacter baumannii population in a major hospital in Kuwait.

Authors:  Leila Vali; Khadija Dashti; Andrés F Opazo-Capurro; Ali A Dashti; Khaled Al Obaid; Benjamin A Evans
Journal:  Front Microbiol       Date:  2015-07-23       Impact factor: 5.640

9.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.

Authors:  Shazad Mushtaq; Zahra Sadouki; Anna Vickers; David M Livermore; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

10.  Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli.

Authors:  Mariana Albano; Melissa J Karau; Audrey N Schuetz; Robin Patel
Journal:  J Clin Microbiol       Date:  2020-12-17       Impact factor: 5.948

View more
  13 in total

1.  Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.

Authors:  Laurent Poirel; Mustafa Sadek; Ayda Kusaksizoglu; Patrice Nordmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-28       Impact factor: 3.267

2.  NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol.

Authors:  Laurent Poirel; José Manuel Ortiz de la Rosa; Zeynep Sakaoglu; Ayda Kusaksizoglu; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-07-11       Impact factor: 5.938

Review 3.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

4.  Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.

Authors:  Laurent Poirel; Jose-Manuel Ortiz de la Rosa; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-03-22       Impact factor: 5.938

5.  Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Marco Falcone; Giusy Tiseo; Alessandro Leonildi; Leonardo Della Sala; Alessandra Vecchione; Simona Barnini; Alessio Farcomeni; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

Review 6.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

7.  Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.

Authors:  Yifan Wang; Yanjun Li; Jin Zhao; Jie Guan; Wentao Ni; Zhancheng Gao
Journal:  Ann Transl Med       Date:  2022-03

8.  Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport.

Authors:  Casin Le; Camila Pimentel; Fernando Pasteran; Marisel R Tuttobene; Tomás Subils; Jenny Escalante; Brent Nishimura; Susana Arriaga; Aimee Carranza; Vyanka Mezcord; Alejandro J Vila; Alejandra Corso; Luis A Actis; Marcelo E Tolmasky; Robert A Bonomo; Maria Soledad Ramírez
Journal:  Biomedicines       Date:  2022-03-03

9.  New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.

Authors:  Dennis Nurjadi; Kaan Kocer; Quan Chanthalangsy; Sabrina Klein; Klaus Heeg; Sébastien Boutin
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.191

10.  Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China.

Authors:  Peng Lan; Ye Lu; Zhongju Chen; Xueqing Wu; Xiaoting Hua; Yan Jiang; Jiancang Zhou; Yunsong Yu
Journal:  Microbiol Spectr       Date:  2022-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.